Letters to the editor
Recommendations for the management of galactosaemia
| The first 150 words of the full text of this article appear below. |
EDITOR,
We were pleased to see the
publication on behalf of the UK Steering Group "Recommendations for
the management of galactosaemia".1 In particular, we
were pleased to see the emphasis on the management of adult women and
the prevention of osteoporosis. We have, however, some concerns about
the advice on the use of Loestrin 20 (an oral contraceptive preparation
containing 20 µg ethinyl oestradiol and a progestogen) for long
term oestrogen replacement.
None of the combined oral contraceptive pills, such as Loestrin 20, are licensed for the prevention of osteoporosis, although until the more widespread use of hormone replacement therapy (HRT) preparations, many were widely used for this purpose. In addition to providing oestrogen, they have the advantage of being without prescription charge and are widely accepted, particularly by young adults.
There are disadvantages, however. The main one is the duration of
therapy. Women taking combined oral contraceptive preparations receive
only
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



